ライフサイエンスコーパス: recombinant vaccine

1 tates and many other countries in favor of a recombinant vaccine.

2 ed the best candidates for generation of the recombinant vaccine.

3 es that would be suitable for inclusion in a recombinant vaccine.

4 ore intranasal booster immunization with the recombinant vaccine.

5 results may explain the high potency of the recombinant vaccine.

6 iruses as gene expression vectors for use as recombinant vaccines.

7 ide to the selection of optimal antigens for recombinant vaccines.

8 llowed researchers to engineer synthetic and recombinant vaccines.

9 er alternative to DryVax and as a vector for recombinant vaccines.

10 ad to improvements in expression vectors and recombinant vaccines.

11 and other poxviruses as human and veterinary recombinant vaccines.

12 vaccines for smallpox- and poxvirus-vectored recombinant vaccines.

13 udies as well as for the development of live recombinant vaccines.

14 y improve the in vivo therapeutic potency of recombinant vaccines.

15 support for the development of an effective recombinant vaccine against hookworm infection in humans

16 ration in efforts to generate antibody-based recombinant vaccines against HCV.

17 r technology for the production of VLP-based recombinant vaccines against infectious diseases.

18 igning a new generation of live, attenuated, recombinant vaccines against the New World alphaviruses.

19 al live-attenuated vaccines, live-attenuated recombinant vaccines allow rational improvement of vacci

20 Both recombinant vaccines also protected against the developm

21 The recombinant vaccine ALVAC-CEA seems to be safe and has b

22 interfering RNAs (DI-RNAs) are generated by recombinant vaccine and wild-type MVs immediately after

23 s been used as the foundation for developing recombinant vaccines and has been used extensively on vi

24 iruses have long been considered vectors for recombinant vaccines and oncolytic therapies.

25 These data should aid in the design of recombinant vaccine antigens to prevent the spread of th

26 rate strong T cell immunity with purified or recombinant vaccine antigens.

27 The fact that the NYVAC-SIV recombinant vaccine appears to be effective per se in th

28 tinued development of the replicating Ad-HIV recombinant vaccine approach and suggest that the use of

29 The recombinant vaccines are the first vaccines against TB m

30 analysis to estimate the hazard ratio of the recombinant vaccine as compared with the standard-dose v

31 reduced in animals that received the MVA-SIV recombinant vaccines as compared with animals that recei

32 are needed on the relative effectiveness of recombinant vaccines as compared with standard-dose vacc

33 have developed, including the production of recombinant vaccines, auxotrophic vaccines, DNA vaccines

34 A recombinant vaccine based on fusion of the circumsporozo

35 s a proof of concept we developed a bivalent recombinant vaccine based on vesicular stomatitis virus

36 hich will very likely impair the efficacy of recombinant vaccines based on the homologous virus.

37 the immunogenicities of single-cycle HIV/SIV recombinant vaccines before initiating studies with nonh

38 Our initial recombinant vaccine, BNSP333-S, expresses a full-length

39 One recombinant vaccine, bvMSP1(42), based on the 42-kDa C-t

40 ese results suggest that a second-generation recombinant vaccine can be rationally engineered to maxi

41 hat vaccination with a parainfluenza virus 5 recombinant vaccine candidate expressing NA (PIV5-NA) fr

42 a challenging task and, to date, protective recombinant vaccine candidates have not been identified.

43 to soluble worm antigen preparation and the recombinant vaccine candidates rSj97, rSj67, and rSj22 f

44 in shaping the glycan epitopes presented on recombinant vaccine candidates.

45 reduced in animals that received the MVA-SIV recombinant vaccines compared with animals that received

46 mmunized systemically or intranasally with a recombinant vaccine composed of domain A of ClfB exhibit

47 The high-dose recombinant vaccine conferred more protection against PC

48 We assessed the efficacy of a recombinant vaccine consisting of outer-surface protein

49 ChimeriVax-WN02 is a live, attenuated recombinant vaccine constructed from an infectious clone

50 A recombinant vaccine containing Aventis Pasteur's canaryp

51 ning 15 ug hemagglutinin [HA]/component) and recombinant vaccine (containing 45 ug HA/component) duri

52 Rabbit antisera against this recombinant vaccine cross-reacted with 10 of the 15 nonv

53 Recombinant vaccines derived from the facultative intrac

54 ve cases of poliomyelitis due to type 2 or 3 recombinant vaccine-derived polioviruses (VDPVs) were re

55 ng that this region may be useful for future recombinant vaccine design.

56 The recombinant vaccine, designated ALVAC-CEA, was administe

57 ue for the inclusion of multiple antigens in recombinant vaccine designs.

58 present technological challenges for simple recombinant vaccine development where a multicomponent m

59 d as a versatile vector with high safety for recombinant vaccine development, addressing unmet medica

60 uate various VACV vectors for the purpose of recombinant vaccine development.

61 lopment of a novel "immunologically optimal" recombinant vaccine expressed in Escherichia coli that e

62 e-in-water emulsion), 2 doses of a canarypox recombinant vaccine expressing CMVgB (ALVAC-CMVgB) follo

63 emic immunization with two human ALVAC-HIV-1 recombinant vaccines expressing Gag, Pol, and gp120 (vCP

64 Recent work on the development of a recombinant vaccine for leishmaniasis has demonstrated t

65 The overall efficacy of a recombinant vaccine for Lyme disease that is effective w

66 denoviral vectors (rAds) are the most potent recombinant vaccines for eliciting CD8(+) T cell-mediate

67 eplicons may be useful in the development of recombinant vaccines for infectious diseases and cancer.

68 The response to recombinant vaccines for Lyme disease was studied to det

69 refining OspA-based vaccines and developing recombinant vaccines for other diseases.

70 , we have developed two safe and efficacious recombinant vaccines for RVF.

71 CR-confirmed influenza were diagnosed in the recombinant-vaccine group and 2435 cases in the standard

72 the ages of 18 and 64 years (632,962 in the recombinant-vaccine group and 997,366 in the standard-do

73 cipants tested positive for influenza in the recombinant-vaccine group as compared with 925 participa

74 novel triple antigen (S, pre-S1, and pre-S2) recombinant vaccine (Hepacare; Medeva Pharma Plc, Speke,

75 Transgenic plants expressing recombinant vaccine immunogens offer an attractive and p

76 urther clinical exploration of the ALVAC-CEA recombinant vaccine in phase I/II studies in protocols d

77 in human vaccinations of using two different recombinant vaccines in diversified prime-and-boost regi

78 so an attractive option for glycoengineering recombinant vaccines in Escherichia coli.

79 the last 25 years, the technology to produce recombinant vaccines in plant cells has evolved from mod

80 The development of new recombinant vaccines, including mRNA and protein nanopar

81 Specifically, receiving the recombinant vaccine is associated with a 17% increase in

82 We show that the recombinant vaccine is associated with a significantly l

83 l increase the practicality of administering recombinant vaccines mucosally.

84 Protein recombinant vaccine NVX-CoV2373 (Novavax) against COVID-

85 that, in an Omicron-dominant period, protein recombinant vaccine NVX-CoV2373 was associated with prot

86 Analogous results were obtained with recombinant vaccines of the same amino acid sequences.

87 unized with vaccine or a control nonvectored recombinant vaccine or HBsAg-expressing vectored MV rema

88 novel triple-antigen (S, pre-S1, and pre-S2) recombinant vaccine or of a present single-antigen (S on

89 (VSV) has long been regarded as a promising recombinant vaccine platform and oncolytic agent but has

90 Microbial KBMA vaccines used either as a recombinant vaccine platform or as a modified form of th

91 Instead, recombinant vaccines provided improved protection in mal

92 man papillomavirus (types 6, 11, 16, and 18) recombinant vaccine (qHPV) in the United States for use

93 influenza A (H3N2 and H1N1) and B virus or a recombinant vaccine (rHAO) containing 15, 45, or 135 mic

94 mbinant bivalent vaccine candidates based on recombinant vaccine strain rabies virus particles, which

95 Z1) for attenuation purposes, generating the recombinant vaccine strains SLT17 (pCZ1) and SLT18 (pCZ1

96 oliovirus live virus vectors are a candidate recombinant vaccine system.

97 ultimately impact human health by advancing recombinant vaccine technology.

98 A recombinant vaccine that mimics the native trimer might

99 Canarypox-CMV pp65 is the first recombinant vaccine to elicit CMV-specific CTL responses

100 ransition from the use of live to the use of recombinant vaccines to compare the risk of dementia bet

101 This thus impairs the ability of recombinant vaccines to serve as factories to produce re

102 OspA is now the basis of a first generation recombinant vaccine undergoing phase III efficacy studie

103 support for the use of L. monocytogenes as a recombinant vaccine vector and show that antivector immu

104 tion with an antigenically complex virus and recombinant vaccine vector.

105 avipoxviruses), which have been developed as recombinant vaccine vectors for permissive (i.e., poultr

106 In addition, many new recombinant vaccine vectors such as vaccinia, Listeria s

107 live vaccine against Marek's disease and as recombinant vaccine viral vectors for protecting against

108 of IL-4 contributes to immune suppression, a recombinant vaccine virus was created which secretes cot

109 dengue serotype-2 virus (DENVax-2) and three recombinant vaccine viruses expressing the prM and E str

110 tegy for the rapid development of comparable recombinant vaccine viruses for human PIV1 and PIV2.

111 A multiepitope and multivariant recombinant vaccine was designed and it was stable, mild

112 The recombinant vaccine was not significantly more protectiv

113 ssociated with HPV, Gardasil, a quadrivalent recombinant vaccine, was developed by Merck & Co., Inc.,

114 to understand the lack of protection of the recombinant vaccine, we determined expression of BB0405

115 The protective efficacy of the recombinant vaccines, with or without an adjuvant, was t